Deep Research Round II: Therapeutic Options and Challenges in Advanced Non-Small Cell Lung Cancer Harbouring the KRAS G12A Mutation

In advanced or metastatic KRAS G12A-mutant NSCLC, there are currently no approved allele-specific targeted agents; first-line management consists of the combination of immunotherapy and chemotherapy, while MEK and RTK combinations as well as pan-RAS inhibitors are undergoing investigational evaluation. From a therapeutic perspective, the G12A variant poses an especially complex challenge due to the lack of direct targeted inhibition, low median survival (9 months [overall survival; G12A and G12V; 150 patients with KRAS-mutant NSCLC who underwent next-generation sequencing at Trakya University Faculty of Medicine between January 2015 and December 2023] OS in a retrospective cohort), poorer immuno-oncology outcomes observed in non-G12C groups, and pronounced intratumoural heterogeneity. Introduction In cases of non-small cell lung cancer (NSCLC), oncogenic mutations in the KRAS gene represent one of the most common oncogenic drivers, occurring in approximately one-quarter to one-third of patients. While specific targeted inhibitors are already available against the most common KRAS variant, G12C, approved allele-specific direct agents are currently unavailable for non-G12C variants such as G12A. The aim of this synthesis is to review the available clinical and experimental data on treatment options for lung cancer harbouring the KRAS G12A mutation, as well as to outline the therapeutic challenges associated with this variant. Methods The review originated from a stored first round. New targeted queries: 2. The full provider log of earlier searches is not available. Automated data extraction and narrative synthesis of available source texts were conducted; this is not a systematic review and does not constitute full-text, independent dual verification. What evidence and potential treatment pathways are currently available in advanced or metastatic non-small cell lung cancer harbouring the KRAS p.G12A mutation? In locally advanced or metastatic non-squamous NSCLC harbouring a KRAS mutation, the combination of immunotherapy and chemotherapy represents the most effective first-line standard systemic therapy, with a retrospective cohort study demonstrating a median PFS of 11.30 months [progression-free survival; ICIs + CHE; 180 patients with KRAS mutation-positive locally advanced or metastatic non-squamous NSCLC treated at the Chinese People's Liberation Army (PLA) General Hospital; first-line], a median OS of 21.24 months [overall survival; ICIs + CHE; 180 patients with KRAS mutation-positive locally advanced or metastatic non-squamous NSCLC treated at the Chinese People's Liberation Army (PLA) General Hospital; first-line], an ORR of 39.29% [objective response rate; ICIs + CHE; 180 patients with KRAS mutation-positive locally advanced or metastatic non-squamous NSCLC treated at the Chinese People's Liberation Army (PLA) General Hospital; first-line], and a DCR of 89.29% [disease control rate; ICIs + CHE; 180 patients with KRAS mutation-positive locally advanced or metastatic non-squamous NSCLC treated at the Chinese People's Liberation Army (PLA) General Hospital; first-line]. Looking specifically at the G12A subgroup, according to a subgroup analysis of a retrospective cohort study, the addition of bevacizumab to first-line chemotherapy reduced median PFS in patients harbouring the G12A variant. In an advanced NSCLC cohort treated with immune checkpoint inhibitors, a retrospective cohort study demonstrated no significant difference in OS or PFS between the major KRAS alleles, including G12A and other types. In the absence of targeted options, the combination of trametinib and anlotinib was evaluated as an experimental therapeutic strategy in advanced non-G12C KRAS-mutant NSCLC in the NCT04967079 trial, showing an ORR of 65% (CI 40.8–84.6) [ORR; trametinib (2 mg) plus anlotinib (8 mg); advanced non-G12C KRAS-mutant NSCLC] and a median PFS of 11.5 months (CI 8.3–15.5) [PFS; trametinib (2 mg) plus anlotinib (8 mg); advanced non-G12C KRAS-mutant NSCLC]. In pretreated advanced KRAS-mutant NSCLC, selinexor plus docetaxel in a multicenter phase I/II dose-escalation trial yielded a partial response of 22 % [partial response; selinexor plus docetaxel; Previously treated advanced KRAS-mutant NSCLC; previously treated advanced] and stable disease of 56% [stable disease; selinexor plus docetaxel; Previously treated, advanced KRAS-mutant Non-Small Cell Lung Cancer; previously treated] regardless of KRAS type, while wild-type TP53 status was associated with improved PFS (HR: 0.2 (CI 0.07–0.67) [progression-free survival; wild-type TP53 vs. TP53-altered; Previously treated advanced KRAS-mutant NSCLC; previously treated advanced]). In preclinical models, the combination of neratinib and pemetrexed induced synergistic cell death in NSCLC cells expressing the G12A variant; furthermore, clinical trials of novel multi-allele or pan-KRAS/pan-RAS compounds such as BBO-11818, BLU-924, S241656, and IMM-1-104 have been initiated. Why does the KRAS p.G12A mutation present a particularly difficult therapeutic challenge in non-small cell lung cancer? The principal challenge in therapy is that currently approved direct KRAS inhibitors exclusively bind to the cysteine residue of the G12C allele, whereas no approved specific targeted inhibitor directed at the G12A allele is available. Regarding clinical outcomes, data from a retrospective cohort study showed that lung cancer patients harbouring the G12A (and G12V) subtype had a median OS of only 9 months [overall survival; G12A and G12V; 150 patients with KRAS-mutant NSCLC who underwent next-generation sequencing at Trakya University Faculty of Medicine between January 2015 and December 2023], falling significantly short of the median survival seen in several other subtypes. The efficacy of immunotherapy is frequently less favorable in non-G12C groups: in a retrospective cohort, non-G12C carriers achieved a substantially shorter median OS compared with the G12C group (6.4 months [overall survival; non-G12C; KRAS-mutant NSCLC patients receiving immune checkpoint inhibitors] vs. 20.7 months [overall survival; G12C; KRAS-mutant NSCLC patients receiving immune checkpoint inhibitors]), and non-G12C mutation was an independent predictor of increased mortality risk (HR: 3.35 (CI 1.26–8.89) [mortality risk (multivariate OS); non-G12C mutation; KRAS-mutant NSCLC patients receiving immune checkpoint inhibitors]). In a retrospective analysis of a large database, patients harbouring non-G12C variants receiving first-line chemoimmunotherapy had a median OS of 24.0 months [overall survival; KRAS non-p.G12C (first-line chemoimmunotherapy); advanced or metastatic lung cancer assessable for KRAS status in the French Epidemiological Strategy and Medical Economics database (2011 to 2021); first-line and second-line], whereas with second-line immunotherapy, the median OS reached 9.4 months (CI 8.0–11.4) [overall survival; KRAS non-p.G12C (second-line immunotherapy); advanced or metastatic lung cancer assessable for KRAS status in the French Epidemiological Strategy and Medical Economics database (2011 to 2021); first-line and second-line]. Treatment response is further complicated by the finding that, among patients receiving first-line immunochemotherapy, non-G12C cases exhibited more pronounced spatial PD-L1 heterogeneity between the primary tumour and metastatic lymph nodes, which compromises the reliability of predictive biomarkers. Discussion Based on available data, there is a marked disparity between the clinical standing of targetable G12C mutations and non-G12C mutations, including G12A. In the absence of approved allele-specific inhibitors, the combination of systemic immunotherapy and chemotherapy represents the standard backbone, while retrospective data suggest that survival in non-G12C groups is frequently less favorable. Discrepancies can be observed across studies regarding the assessment of immunotherapy outcomes: while some analyses demonstrated significantly inferior OS in non-G12C subgroups, other retrospective cohorts showed no significant difference in OS or PFS across the primary mutational types, including G12A. The direction of therapeutic development points partly toward the combined blockade of downstream MAPK pathways or other targets (such as MEK and RTK inhibition), and partly toward early-phase clinical evaluation of novel multi-allele and pan-RAS inhibitors. Limitations A major limitation of the literature is that the vast majority of studies evaluate data under an aggregated non-G12C category; consequently, clinical trials focusing specifically on the G12A allele with adequate sample size and statistical power are scarce. Direct evidence regarding G12A originates almost exclusively from single-centre retrospective observational studies, early-phase trials, or in vitro cell line models. Conclusion In advanced or metastatic KRAS G12A-mutant NSCLC, there are currently no approved allele-specific targeted agents; first-line management consists of the combination of immunotherapy and chemotherapy, while MEK and RTK combinations as well as pan-RAS inhibitors are undergoing investigational evaluation. From a therapeutic perspective, the G12A variant poses an especially complex challenge due to the lack of direct targeted inhibition, low median survival (9 months [overall survival; G12A and G12V; 150 patients with KRAS-mutant NSCLC who underwent next-generation sequencing at Trakya University Faculty of Medicine between January 2015 and December 2023] OS in a retrospective cohort), poorer immuno-oncology outcomes observed in non-G12C groups, and pronounced intratumoural heterogeneity.

Deep Research Round II: Therapeutic Options and Challenges in Advanced Non-Small Cell Lung Cancer Harbouring the KRAS G12A Mutation

References